FLX193 is a best-in-class highly-potent and selective CCR4 antagonist for the treatment of allergic disorders including atopic dermatitis (eczema) and asthma. FLX193 works by blocking CCR4 on Th2 cells which have been shown to play a key role in many allergic diseases. When CCL17 and CCL22 bind to CCR4 on Th2 cells, Th2 cells activate specific cytokines (IL-4, IL-5 and IL-13) that begin an allergic cascade in the lungs, skin and nasal passage. We have shown the ability to block Th2 cells from entering inflamed lung and skin. We believe we have a rapid path to a clinical proof-of-concept with this molecule by conducting a small study in patients with atopic dermatitis.

We expect to begin clinical testing in 2019.